Web Desc
Advances in the Understanding and Treatment of Melanoma
Organizer(s): Patrick Hwu, Elizabeth Grimm and James Mulé
Date: January 18 - 23, 2006
Location: Hilton Santa Fe Historic Plaza Hotel, Santa Fe, NM, USA
Supported by The Director's Fund
For important information on the coronavirus, please click here
Summary of Meeting:
Because of its inherent immunogenicity and abundant vascularity, melanoma provides a unique opportunity to develop novel molecular, immunologic and anti-angiogenic therapies that can then be generalized to other diseases. Some consider melanoma the 'E.coli' in which to develop new cancer therapies. Three of the most exciting areas in this field involve molecular targeting of specific pathways, cancer vaccines and immunotherapy, and anti-vascular therapies. However, none of these areas alone are likely to have significant impact in the disease, and the use of multiple approaches will be critical. While there are many meetings which focus on a particular treatment approach, this program will bring together a multidisciplinary group that will explore the interactions among these distinct therapeutic strategies. We envision that basic and clinical research in melanoma will lead the way in integrating molecular targeting, immunologic, and anti-vascular therapies and can serve as a model for the treatment of other diseases.
Scholarship Deadline: September 19 2005
Discounted Abstract Deadline: September 19 2005
Abstract Deadline: October 11 2005
Discounted Registration Deadline: November 18 2005
We gratefully acknowledge additional support for this conference from:
Melanoma Research FoundationNovartis Institutes for BioMedical ResearchSchering-Plough Corporation
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

3M Pharmaceuticals

Chiron Corporation
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1 R13 CA117400-01
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Wednesday, January 18 | 3:00PM - 7:30PM
Registration
Room: Promenade


Wednesday, January 18 | 6:30PM - 7:30PM
Refreshments
Room: Promenade


Wednesday, January 18 | 7:30PM - 8:30PM
Keynote Address
Room: Mesa A-B

Speaker 1 of 1
Richard M. Marais, Cancer Research UK Manchester Institute, UK
Mechanisms of RAF Signaling in Cancer

Thursday, January 19 | 7:00AM - 8:00AM
Breakfast
Room: Chamisa


Thursday, January 19 | 8:00AM - 11:00AM
Epidemiology and Prevention of Melanoma
Room: Mesa A-B

Speaker 1 of 4
Margaret A. Tucker, National Cancer Institute, National Institutes of Health, USA
Who is at Risk of Melanoma?

Thursday, January 19 | 8:00AM - 11:00AM
Epidemiology and Prevention of Melanoma
Room: Mesa A-B

Speaker 2 of 4
* Marianne Berwick, University of New Mexico Health Sciences Center, USA
Gene-Environment Interactions in Melanoma

Thursday, January 19 | 8:00AM - 11:00AM
Epidemiology and Prevention of Melanoma
Room: Mesa A-B

Speaker 3 of 4
Qingyi Wei, University of Texas MD Anderson Cancer Center, USA
DNA Repair and Susceptibility to Melanoma

Thursday, January 19 | 8:00AM - 11:00AM
Epidemiology and Prevention of Melanoma
Room: Mesa A-B

Speaker 4 of 4
Christina K. Augustine, Duke University and VA Medical Centers, USA
Short talk: Optimizing Regional Melanoma Therapy Using Pharmacogenomic Strategies

Thursday, January 19 | 9:20AM - 9:40AM
Coffee Break
Room: Promenade


Thursday, January 19 | 11:00AM - 1:00PM
Poster Setup
Room: Ortiz


Thursday, January 19 | 1:00PM - 10:00PM
Poster Viewing
Room: Ortiz


Thursday, January 19 | 2:00PM - 4:30PM
Workshop 1: Melanoma Immunotherapy
Room: Mesa A-B

Speaker 1 of 6
* Bernard A. Fox, Earle A Chiles Research Institute, USA
Exploiting Lymphopenia to Augment Vaccine Efficacy

Thursday, January 19 | 2:00PM - 4:30PM
Workshop 1: Melanoma Immunotherapy
Room: Mesa A-B

Speaker 2 of 6
* James J. Mulé, H. Lee Moffitt Cancer Center & Research Institute, USA

Thursday, January 19 | 2:00PM - 4:30PM
Workshop 1: Melanoma Immunotherapy
Room: Mesa A-B

Speaker 3 of 6
Daniel E. Speiser, Ludwig Center, University of Lausanne, Switzerland
Ex Vivo Detectable Human CD8 T-Cell Responses to CT Antigens in 4/4 Patients Vaccinated with Stable Peptide / IFA Emulsions

Thursday, January 19 | 2:00PM - 4:30PM
Workshop 1: Melanoma Immunotherapy
Room: Mesa A-B

Speaker 4 of 6
Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, USA
Clinical Development of DNA Vaccines for Melanoma

Thursday, January 19 | 2:00PM - 4:30PM
Workshop 1: Melanoma Immunotherapy
Room: Mesa A-B

Speaker 5 of 6
Christopher A. Klebanoff, Memorial Sloan Kettering Cancer Center, USA
Removal of Homeostatic Cytokine Sinks by Lymphodepletion Enhances the Efficacy of Adoptively Transferred Tumor-Specific CD8+ T Cells

Thursday, January 19 | 2:00PM - 4:30PM
Workshop 1: Melanoma Immunotherapy
Room: Mesa A-B

Speaker 6 of 6
Karen Hastings, University of Arizona College of Medicine, USA
Lysosomal Thiol Reductase GILT is Essential for MHC Class II Processing of Melanocyte Differentiation Antigen TRP-1

Thursday, January 19 | 4:30PM - 5:00PM
Coffee Available
Room: Promenade


Thursday, January 19 | 5:00PM - 7:00PM
Prognostic Markers for Melanoma Progression
Room: Mesa A-B

Speaker 1 of 4
* James J. Mulé, H. Lee Moffitt Cancer Center & Research Institute, USA

Thursday, January 19 | 5:00PM - 7:00PM
Prognostic Markers for Melanoma Progression
Room: Mesa A-B

Speaker 2 of 4
David S.B. Hoon, John Wayne Cancer Institute, USA
Prognostic Markers for Melanoma Progression

Thursday, January 19 | 5:00PM - 7:00PM
Prognostic Markers for Melanoma Progression
Room: Mesa A-B

Speaker 3 of 4
David E. Elder, University of Pennsylvania School of Medicine, USA
Markers of Tumor Progression, Diagnosis and Prognosis in Melanoma

Thursday, January 19 | 5:00PM - 7:00PM
Prognostic Markers for Melanoma Progression
Room: Mesa A-B

Speaker 4 of 4
David Rimm, Yale University, USA
Quantitative Multiplexed Analysis of TMAs to Discover Prognostic Factors for Melanoma

Thursday, January 19 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Ortiz/Chamisa


Thursday, January 19 | 7:30PM - 10:00PM
Poster Session 1
Room: Ortiz/Chamisa


Friday, January 20 | 7:00AM - 8:00AM
Breakfast
Room: Chamisa


Friday, January 20 | 8:00AM - 11:00AM
Molecular Biology of Melanoma I
Room: Mesa A-B

Speaker 1 of 5
* Meenhard Herlyn, Wistar Institute, USA
Targeting Signaling Pathways for Melanoma Therapy

Friday, January 20 | 8:00AM - 11:00AM
Molecular Biology of Melanoma I
Room: Mesa A-B

Speaker 2 of 5
Peter Hersey, University of Newcastle, Australia
TRAIL Biology and Melanoma


Friday, January 20 | 8:00AM - 11:00AM
Molecular Biology of Melanoma I
Room: Mesa A-B

Speaker 3 of 5
Ann Richmond, Vanderbilt University School of Medicine, USA
Targeting NF-kappaB and Autocrine Signaling Pathways in Melanoma

Friday, January 20 | 8:00AM - 11:00AM
Molecular Biology of Melanoma I
Room: Mesa A-B

Speaker 4 of 5
Bahija Jallal, Immunocore LLC, USA
Targeted Therapeutics in Melanoma: Changing the Front End of Drug Development

Friday, January 20 | 8:00AM - 11:00AM
Molecular Biology of Melanoma I
Room: Mesa A-B

Speaker 5 of 5
Penny Emma Lovat, Newcastle University, UK
Short Talk: Fenretinide-Induced Apoptosis Via Endoplasmic Reticulum Stress- New Drug Targets for Melanoma Therapy?

Friday, January 20 | 9:20AM - 9:40AM
Coffee Break
Room: Promenade


Friday, January 20 | 2:00PM - 4:30PM
Workshop 2: Staging and Biomarkers
Room: Mesa A-B

Speaker 1 of 7
* Vernon K. Sondak, H. Lee Moffitt Cancer Center & Research Institute, USA
The Need for New Biomarkers of Melanoma Nodal Metastasis

Friday, January 20 | 2:00PM - 4:30PM
Workshop 2: Staging and Biomarkers
Room: Mesa A-B

Speaker 2 of 7
* Merrick I. Ross, University of Texas MD Anderson Cancer Center, USA
Future Approaches to Melanoma Staging

Friday, January 20 | 2:00PM - 4:30PM
Workshop 2: Staging and Biomarkers
Room: Mesa A-B

Speaker 3 of 7
Steven Everett, Ninewells Hospital & Medical School, UK
Cytochrome P450 Cyp1b1 Expression in Primary and Metastatic Melanoma

Friday, January 20 | 2:00PM - 4:30PM
Workshop 2: Staging and Biomarkers
Room: Mesa A-B

Speaker 4 of 7
Stergios Moschos, University of Pittsburgh Medical Center, USA
Ubc9, is the Most Highly Expressed Protein in Melanoma Infiltrated Lymph Nodes and its Downregulation, Alone or in Combination with Chemotherapy/Radiation, Increases Cell Death in Melanoma Cell Lines

Friday, January 20 | 2:00PM - 4:30PM
Workshop 2: Staging and Biomarkers
Room: Mesa A-B

Speaker 5 of 7
Phyllis A. Gimotty, University of Pennsylvania, USA
Staging Thin (< 1.00mm) Invasive Cutaneous Melanomas

Friday, January 20 | 2:00PM - 4:30PM
Workshop 2: Staging and Biomarkers
Room: Mesa A-B

Speaker 6 of 7
Rosalynn M. Nazarian, Massachusetts General Hospital, USA
Mitf, Bcl-2 and Inos Expression in Melanocytic Tumor Progression Using a Tissue Microarray Approach

Friday, January 20 | 2:00PM - 4:30PM
Workshop 2: Staging and Biomarkers
Room: Mesa A-B

Speaker 7 of 7
Jeffrey E. Gershenwald, University of Texas MD Anderson Cancer Center, USA
Heterogeneity of Microscopic Stage III Melanoma in the SLN Era: Implications for AJCC/UICC Staging and Future Clinical Trial Design

Friday, January 20 | 4:30PM - 5:00PM
Coffee Available
Room: Promenade


Friday, January 20 | 5:00PM - 7:00PM
Molecular Biology of Melanoma II
Room: Mesa A-B

Speaker 1 of 3
Frank Meyskens, University of California, Irvine, USA
The Pathogenesis of Human Melonoma is a Redox-Driven/Regulated Process: Etiologic, Preventitive and Therapeutic Implications

Friday, January 20 | 5:00PM - 7:00PM
Molecular Biology of Melanoma II
Room: Mesa A-B

Speaker 2 of 3
* Elizabeth A. Grimm, University of Texas MD Anderson Cancer Center, USA
Role of Endogenous Nitric Oxide in Melanoma

Friday, January 20 | 5:00PM - 7:00PM
Molecular Biology of Melanoma II
Room: Mesa A-B

Speaker 3 of 3
Somasekar Seshagiri, Genentech, Inc., USA
Short Talk: Oncogenic BRAF is Required for Tumor Growth and Maintenance in Melanoma Models

Friday, January 20 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Ortiz/Chamisa


Saturday, January 21 | 7:00AM - 8:00AM
Breakfast
Room: Chamisa


Saturday, January 21 | 8:00AM - 11:00AM
Preclinical Studies of Melanoma Immunotherapy
Room: Mesa A-B

Speaker 1 of 5
Herbert B. Slade, DFB Pharmaceuticals, USA
Application of Toll-Like Receptor 7/8 Agonists in Cancer Therapy

Saturday, January 21 | 8:00AM - 11:00AM
Preclinical Studies of Melanoma Immunotherapy
Room: Mesa A-B

Speaker 2 of 5
Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
Melanoma-Associated Genetic Mutations Targeted by Human CD4+ T Cells

Saturday, January 21 | 8:00AM - 11:00AM
Preclinical Studies of Melanoma Immunotherapy
Room: Mesa A-B

Speaker 3 of 5
* Patrick Hwu, University of Texas MD Anderson Cancer Center, USA
Murine Plasmacytoid Dendritic Cells Synergize with Myeloid Dendritic Cells and NK Cells in the Induction of Anti-Tumor Immune Responses In Vivo

Saturday, January 21 | 8:00AM - 11:00AM
Preclinical Studies of Melanoma Immunotherapy
Room: Mesa A-B

Speaker 4 of 5
Giorgio Parmiani, Fondazione Centro San Raffaele Del MonteTabor, Italy
New Immunosuppressive Mechanisms in Melanoma Patients

Saturday, January 21 | 8:00AM - 11:00AM
Preclinical Studies of Melanoma Immunotherapy
Room: Mesa A-B

Speaker 5 of 5
Thomas S. Kupper, Brigham and Women's Hospital, USA
Short Talk: Approaches to Optimizing Melanoma Immunotherapy

Saturday, January 21 | 9:20AM - 9:40AM
Coffee Break
Room: Promenade


Saturday, January 21 | 11:00AM - 1:00PM
Poster Setup
Room: Ortiz


Saturday, January 21 | 1:00PM - 10:00PM
Poster Viewing
Room: Ortiz


Saturday, January 21 | 2:00PM - 4:30PM
Panel Discussion: Overcoming Barriers to Translational Resea
rch
Room: Mesa A-B

Speaker 1 of 3
* Lynn Schuchter, University of Pennsylvania, USA

Saturday, January 21 | 2:00PM - 4:30PM
Panel Discussion: Overcoming Barriers to Translational Resea
rch
Room: Mesa A-B

Speaker 2 of 3
* Walter J. Urba, Earle A. Chiles Research Institute, USA

Saturday, January 21 | 2:00PM - 4:30PM
Panel Discussion: Overcoming Barriers to Translational Resea
rch
Room: Mesa A-B

Speaker 3 of 3
Francesco M. Marincola, Sidra Medical and Research Center, Qatar
Title to be Determined

Saturday, January 21 | 4:30PM - 5:00PM
Coffee Available
Room: Promenade


Saturday, January 21 | 5:00PM - 7:00PM
Melanoma Clinical Immunotherapy Trials
Room: Mesa A-B

Speaker 1 of 4
* Jeffrey Weber, New York University, USA
Phase II Trials of Class II Melanoma Peptides and Class I Peptides with IL-12 and Alum for Resected High Risk Melanoma

Saturday, January 21 | 5:00PM - 7:00PM
Melanoma Clinical Immunotherapy Trials
Room: Mesa A-B

Speaker 2 of 4
Thomas Gajewski, University of Chicago, USA
Gene Expression Profile of Melanoma Tumor Microenvironment Associated with Favorable Clinical Outcome to a Multipeptide Vaccine

Saturday, January 21 | 5:00PM - 7:00PM
Melanoma Clinical Immunotherapy Trials
Room: Mesa A-B

Speaker 3 of 4
A. Karolina Palucka, The Jackson Laboratory for Genomic Medicine, USA
Dendritic Cell Vaccines in Melanoma

Saturday, January 21 | 5:00PM - 7:00PM
Melanoma Clinical Immunotherapy Trials
Room: Mesa A-B

Speaker 4 of 4
F. Stephen Hodi, Dana-Farber Cancer Institute, USA
Short Talk: Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Antibody Blockade in Previously Vaccinated Melanoma and Ovarian Cancer Patients

Saturday, January 21 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Ortiz/Chamisa


Saturday, January 21 | 7:30PM - 10:00PM
Poster Session 2
Room: Ortiz/Chamisa


Sunday, January 22 | 7:00AM - 8:00AM
Breakfast
Room: Chamisa


Sunday, January 22 | 8:00AM - 11:00AM
Antivascular Approaches for Melanoma
Room: Mesa A-B

Speaker 1 of 4
* Menashe Bar-Eli, University of Texas MD Anderson Cancer Center, USA
Gene Regulation in Melanoma Angiogenesis

Sunday, January 22 | 8:00AM - 11:00AM
Antivascular Approaches for Melanoma
Room: Mesa A-B

Speaker 2 of 4
Mary J.C. Hendrix, Children's Memorial Research Center at Northwestern University, USA
The Clinical Implications of Melanoma Tumor Cell Plasticity

Sunday, January 22 | 8:00AM - 11:00AM
Antivascular Approaches for Melanoma
Room: Mesa A-B

Speaker 3 of 4
Wen-Jen Hwu, University of Texas MD Anderson Cancer Center, USA
Treatment of Melanoma with Thalidomide and Its Analogues: Antivascular, and Immunomodulatory Activity

Sunday, January 22 | 8:00AM - 11:00AM
Antivascular Approaches for Melanoma
Room: Mesa A-B

Speaker 4 of 4
Steven K. Libutti, Albert Einstein College of Medicine, USA
Clinical Trials of Antivascular Agents in Melanoma

Sunday, January 22 | 9:20AM - 9:40AM
Coffee Break
Room: Promenade


Sunday, January 22 | 2:00PM - 4:30PM
Workshop 3: Melanoma Signal Transduction and Targeted Therap
ies
Room: Mesa A-B

Speaker 1 of 6
* Frank G. Haluska, ARIAD Pharmaceuticals, Inc., USA

Sunday, January 22 | 2:00PM - 4:30PM
Workshop 3: Melanoma Signal Transduction and Targeted Therap
ies
Room: Mesa A-B

Speaker 2 of 6
* Jeffrey E. Lee, University of Texas MD Anderson Cancer Center, USA

Sunday, January 22 | 2:00PM - 4:30PM
Workshop 3: Melanoma Signal Transduction and Targeted Therap
ies
Room: Mesa A-B

Speaker 3 of 6
Staffan Stromblad, Karolinska Institutet, Sweden
Rescue of Integrin alphaV-Dependent Unfolding of Wild Type p53 Suppresses Melanoma Tumor Growth

Sunday, January 22 | 2:00PM - 4:30PM
Workshop 3: Melanoma Signal Transduction and Targeted Therap
ies
Room: Mesa A-B

Speaker 4 of 6
Romina Marone, Institute of Biochemistry and Genetics, Switzerland
Targeting Melanoma – Which Phosphoinositide 3-Kinase Isoform?

Sunday, January 22 | 2:00PM - 4:30PM
Workshop 3: Melanoma Signal Transduction and Targeted Therap
ies
Room: Mesa A-B

Speaker 5 of 6
Kevin B. Kim, University of Texas MD Anderson Cancer Center, USA
Changes in Expressions of Phosphorylated-AKT in Metastatic Melanoma Lesions after Imatinib Treatment

Sunday, January 22 | 2:00PM - 4:30PM
Workshop 3: Melanoma Signal Transduction and Targeted Therap
ies
Room: Mesa A-B

Speaker 6 of 6
Alexander J.F. Lazar, University of Texas MD Anderson Cancer Center, USA
PTEN Expression, BRAF and NRAS Mutational Status in Primary Cutaneous Melanoma

Sunday, January 22 | 4:30PM - 5:00PM
Coffee Available
Room: Promenade


Sunday, January 22 | 5:00PM - 5:45PM
Workshop 4: Epidemiology and Molecular Biology
Room: Mesa A-B

Speaker 1 of 4
* Thomas S. Kupper, Brigham and Women's Hospital, USA

Sunday, January 22 | 5:00PM - 5:45PM
Workshop 4: Epidemiology and Molecular Biology
Room: Mesa A-B

Speaker 2 of 4
Craig Ceol, Children's Hospital Boston, USA
Short Talk: Using the Zebrafish to Identify and Characterize Mutations that Cause Melanoma

Sunday, January 22 | 5:00PM - 5:45PM
Workshop 4: Epidemiology and Molecular Biology
Room: Mesa A-B

Speaker 3 of 4
Michael Ming, University of Pennsylvania, USA
Short Talk: Statins, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Calcium Channel bBockers (CCBs) are Prescribed Less Frequently for Patients who Later Develop Melanoma

Sunday, January 22 | 5:00PM - 5:45PM
Workshop 4: Epidemiology and Molecular Biology
Room: Mesa A-B

Speaker 4 of 4
Levi A. Garraway, Genentech, Inc, USA
Short Talk: Linking Genetic Dependency to Therapeutic Vulnerability in
Melanoma


Sunday, January 22 | 5:45PM - 6:45PM
Concluding Keynote Address
Room: Mesa A-B

Speaker 1 of 1
Michael B. Atkins, Georgetown Lombardi Comprehensive Cancer Center, USA
The Future of Melanoma Therapy

Sunday, January 22 | 6:45PM - 7:00PM
Announcement of Poster Contest Winners

Speaker 1 of 1
* Patrick Hwu, University of Texas MD Anderson Cancer Center, USA

Sunday, January 22 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Mesa C


Sunday, January 22 | 8:00PM - 11:00PM
Entertainment
Room: Mesa C


Sunday, January 22 | 8:00PM - 11:00PM
Cash Bar
Room: Mesa C


Monday, January 23 | 10:21AM - 10:21AM
Departure


*Session Chair
†Invited, not yet responded.